{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:34:01Z","timestamp":1790685241214,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T11:25:38Z","timestamp":1592911538000},"page":"343-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Addictovigilance contribution during COVID-19 epidemic and lockdown in France"],"prefix":"10.1016","volume":"75","author":[{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Jouanjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chaouachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Deheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fouilh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chistine","family":"Fournier-Choma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryl\u00e8ne","family":"Guerlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynald","family":"Le Boisselier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Tournebize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.06.006_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.001","article-title":"French network of regional pharmacovigilance c. Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data","author":"Grandvuillemin","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.06.006_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.002","article-title":"\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","author":"Gerard","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.06.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.003","article-title":"French Society of Pharmacology T. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection","author":"Micallef","year":"2020","journal-title":"Therapies"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0250","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/fcp.12564","article-title":"Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic","volume":"34","author":"Larrouquere","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0260","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-016-0497-7","article-title":"Comment on: \u201cSocial media mining for toxicovigilance: automatic monitoring of prescription medication abuse from Twitter\u201d","volume":"40","author":"Jouanjus","year":"2017","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.therap.2020.06.006_bib0265","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/ijnp\/pyz033","article-title":"Comment on: An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions","volume":"22","author":"Jouanjus","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2018.07.007","article-title":"From psychoactive medicines to addictovigilance in French Public Health Code (1990\u20132017)","volume":"74","author":"Baumevieille","year":"2019","journal-title":"Therapies"},{"issue":"1","key":"10.1016\/j.therap.2020.06.006_bib0275","first-page":"15","article-title":"The French system of evaluation of dependence: establishment in a legal system","volume":"56","author":"Baumevieille","year":"2001","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapies"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0285","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0290","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00002018-200730030-00007","article-title":"Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey","volume":"30","author":"Boeuf","year":"2007","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.therap.2020.06.006_bib0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/fcp.12368","article-title":"Tamper-resistant prescription forms for narcotics in France: should we generalize them?","volume":"32","author":"Daveluy","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.therap.2020.06.006_bib0300","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00414-008-0291-x","article-title":"Chemical submission: results of 4-year French inquiry","volume":"123","author":"Djezzar","year":"2009","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.therap.2020.06.006_bib0310","series-title":"D\u00e9c\u00e8s directement li\u00e9s aux drogues. In: Toxicomanie OFdDe, (Ed)","first-page":"1","author":"Brisacier","year":"2019"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0315","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.therap.2018.09.078","article-title":"Interest of large electronic health care databases in addictovigilance: lessons from 15 years of pharmacoepidemiological contribution","volume":"74","author":"Dupui","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.06.006_bib0320","article-title":"Ten-year trend of opioid and non-opioid analgesic use in the French adult population","author":"Daveluy","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0325","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.therap.2019.06.002","article-title":"A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France","volume":"74","author":"Auffret","year":"2019","journal-title":"Therapies"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0330","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/fcp.12401","article-title":"Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?","volume":"32","author":"Gentile","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.06.006_bib0335","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.addbeh.2017.11.021","article-title":"Parachuting psychoactive substances: pharmacokinetic clues for harm reduction","volume":"78","author":"Daveluy","year":"2018","journal-title":"Addict Behav"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0340","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.therap.2016.07.001","article-title":"Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres","volume":"71","author":"Peyriere","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.06.006_bib0345","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuro.2020.03.015","article-title":"Use of new psychoactive substances to mimic prescription drugs: The trend in France","volume":"79","author":"Batisse","year":"2020","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.therap.2020.06.006_bib0350","doi-asserted-by":"crossref","first-page":"44428","DOI":"10.1038\/srep44428","article-title":"Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): derivation and validation of a model","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.therap.2020.06.006_bib0355","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2515\/therapie\/2012064","article-title":"Les CAARUD, lieux privil\u00e9gi\u00e9s d\u2019\u00e9mergence de signaux pour l\u2019addictovigilance","volume":"67","author":"Moracchini","year":"2012","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.06.006_bib0360","article-title":"Arr\u00eat\u00e9 du 19 mars 2020 compl\u00e9tant l\u2019arr\u00eat\u00e9 du 14 mars 2020 portant diverses mesures relatives \u00e0 la lutte contre la propagation du virus COVID-19","volume":"0069","author":"Ministre des Solidarit\u00e9s et de la Sant\u00e9","year":"2020","journal-title":"JORF"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0365","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.therap.2018.07.001","article-title":"Int\u00e9r\u00eat de la mise \u00e0 disposition de la naloxone aupr\u00e8s des usagers de drogues pour le traitement d\u2019urgence de surdosage d\u2019opio\u00efdes","volume":"73","author":"Frauger","year":"2018","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0370","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.therap.2018.09.070","article-title":"Am\u00e9liorer la balance b\u00e9n\u00e9fices\/risques de la m\u00e9thadone en respectant ses sp\u00e9cificit\u00e9s pharmacologiques","volume":"74","author":"Frauger","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.06.006_bib0375","article-title":"Psychopathological consequences of confinement","volume":"22","author":"Mengin","year":"2020","journal-title":"Encephale"},{"key":"10.1016\/j.therap.2020.06.006_bib0380","series-title":"Pharmacovigilance et addictovigilance dans le contexte du COVID-19: une surveillance renforc\u00e9e","author":"ANSM","year":"2020"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00228-014-1783-x","article-title":"Detection of signals of abuse and dependence applying disproportionality analysis","volume":"71","author":"Pauly","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2020.06.006_bib0390","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/bcp.13272","article-title":"Early signal of diverted use of tropicamide eye drops in France","volume":"83","author":"Ponte","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.06.006_bib0395","article-title":"Le m\u00e9susage du fentanyl en France\u00a0: 2010\u00a0\u00e0 2015","volume":"25","author":"Tournebize","year":"2019","journal-title":"Therapies"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0400","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.therap.2016.04.006","article-title":"Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history","volume":"71","author":"Driot","year":"2016","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.therap.2020.06.006_bib0405","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0410","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2515\/therapie\/2015006","article-title":"Drug abuse monitoring: which pharmacoepidemiological resources at the European level?","volume":"70","author":"Lapeyre-Mestre","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.06.006_bib0415","article-title":"Warning on increased serious health complications related to non-medical use of nitrous oxide","volume":"17","author":"Micallef","year":"2020","journal-title":"Therapies"},{"issue":"7","key":"10.1016\/j.therap.2020.06.006_bib0420","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3280","article-title":"Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse","volume":"21","author":"Jouanjus","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.therap.2020.06.006_bib0425","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2010.00882.x","article-title":"Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network","volume":"25","author":"Frauger","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.therap.2020.06.006_bib0430","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000346179","article-title":"Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France","volume":"19","author":"Peyriere","year":"2013","journal-title":"Eur Addict Res"},{"issue":"2","key":"10.1016\/j.therap.2020.06.006_bib0435","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2515\/therapie\/2015012","article-title":"Example of an investigation of an \u201cemergent\u201d phenomenon in addiction vigilance: the case of methylphenidate","volume":"70","author":"Micallef","year":"2015","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2020.06.006_bib0440","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.06.006_bib0445","article-title":"Pharmaciens d\u2019officine, \u00e9tudiants en pharmacie et demandes de m\u00e9dicaments \u00e0 base de cod\u00e9ine: \u00e9tude observationnelle","author":"Baumevieille","year":"2019","journal-title":"Therapies"},{"issue":"9","key":"10.1016\/j.therap.2020.06.006_bib0450","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40261-016-0421-z","article-title":"Disproportionality analysis for the assessment of abuse and dependence potential of pregabalin in the French Pharmacovigilance database","volume":"36","author":"Bossard","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"11","key":"10.1016\/j.therap.2020.06.006_bib0455","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/pds.4624","article-title":"Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study","volume":"27","author":"Jouanjus","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2020.06.006_bib0460","series-title":"Site de l\u2019association fran\u00e7aise des centres d\u2019addictovigilance. Addictovigilance, situation COVID-19","author":"Addictovigilance","year":"2020"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:04Z","timestamp":1758567244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720301104"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}